Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
Sep 20, 2019
Three different biotech ETFs, three bearish signals with high confidence

Three different biotech ETFs, three bearish signals with high confidence

The biotech sector has been trending lower for the last five months, but has seen a bit of a rally over the last few weeks as investors appear to be making a shift from growth stocks to value stocks. Because of this rotation, many stocks in the sector are in overbought territory, at least on the daily charts. When I ran my nightly scans on Thursday night, I found three different biotech ETFs on my bearish scan and then I found that all three had seen bearish signals generated by the Tickeron Trend Prediction Engine.

The iShares Nasdaq Biotechnology ETF (Nasdaq: IBB), the Direxion Daily S&P Biotech Bull 3x Shares (AMEX: LABU), and the SPDR S&P Biotech ETF (NYSE: XBI) are the three ETFs appearing on my bearish list.

Let’s look at each one individually. The IBB has been trending lower since early April and a downward sloped trend channel has formed in the last five months. The fund just hit the upper rail of the channel and that upper rail is in the same vicinity as the 50-day moving average.

The daily stochastic readings are in overbought territory and made a bearish crossover on September 19. The bearish signal from the Tickeron Trend Prediction Engine came on September 17. The signal shows a confidence level of 71% and it shows that 85% of past predictions on the IBB have been successful. The signal calls for a decline of at least 4% within the next month.

In addition to bearish signal from Tickeron, the technical analysis overview shows that the price moved below its 50-day Moving Average, which indicates a reversal from an uptrend to a downtrend. In 35 of 40 cases where IBB's price crossed below its 50-day Moving Average, its price fell further within the subsequent month. The odds of a continued downtrend are 88%.

Turning our attention to the leveraged LABU fund, we see that it peaked around the same time as the IBB. There trend line connecting the highs is cleaner than the upper rail of the channel on the IBB, but there isn’t a parallel lower rail that would form a channel.

Like we saw on the IBB chart, the daily stochastic readings for LABU are in overbought territory and made a bearish crossover on September 19. The Tickeron Trend Prediction Engine generated a bearish signal on September 17 as well. The signal for this ETF showed a confidence level of 80% while past predictions have been successful 97% of the time.

Additionally, the Tickeron Technical Analysis Overview shows that the higher Bollinger Band was broken. A price fall is expected as the ticker heads toward the middle band. In 37 of 38 cases where LABU's price broke its higher Bollinger Band, its price dropped further during the following month. The odds of a continued downtrend are 90%.

Finally, the chart for the XBI looks a little different from the other two ETFs. Yes, the fund peaked in April, but it has seen a trend channel form over the last three months and it just hit the upper rail of the channel this week. Like the IBB channel, the upper rail of the XBI channel is in close proximity to the 50-day moving average.

As we saw with the other two, the stochastic readings are in overbought territory and made a bearish crossover, and we have the bearish signal from Tickeron on September 17. The signal for the XBI showed a confidence level of 75% and past predictions were successful 90% of the time.

For the XBI, there were several other bearish factors on the technical analysis overview. First, the fund moved above its higher Bollinger Band on September 11, 2019. This price move signals that XBI may fall back below the higher band and head toward the middle band. In 39 of 43 cases where XBI's price broke its higher Bollinger Band, its price dropped further during the following month. The odds of a continued downtrend are 90%.

On September 12, the 50-day moving average crossed below its 200-day moving average and that indicates a sell signal, due to the trend repositioning lower. In 3 of 3 cases where XBI's 50-day moving average crossed below its 200-day moving average, its price fell further within the subsequent month. The odds of a continued downtrend are 90%.

And like we saw on the IBB, the XBI saw its price drop below the 50-day moving average, which indicates a reversal from an uptrend to a downtrend. In 36 of 42 cases where XBI's price crossed below its 50-day moving average, its price fell further within the subsequent month. The odds of a continued downtrend are 86%.

Related Ticker: IBB

IBB's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for IBB turned positive on June 11, 2026. Looking at past instances where IBB's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on June 15, 2026. You may want to consider a long position or call options on IBB as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

IBB moved above its 50-day moving average on June 11, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for IBB crossed bullishly above the 50-day moving average on June 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IBB advanced for three days, in of 323 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 231 cases where IBB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 15 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

IBB broke above its upper Bollinger Band on June 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), IQVIA Holdings (NYSE:IQV), Biogen (NASDAQ:BIIB), Moderna (NASDAQ:MRNA), Illumina (NASDAQ:ILMN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR).

Industry description

The investment seeks to track the investment results of the NYSE Biotechnology Index composed of U.S.-listed equities in the biotechnology sector. The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

Market Cap

The average market capitalization across the iShares Biotechnology ETF ETF is 7.63B. The market cap for tickers in the group ranges from 14.86M to 198.61B. AMGN holds the highest valuation in this group at 198.61B. The lowest valued company is APLT at 14.86M.

High and low price notable news

The average weekly price growth across all stocks in the iShares Biotechnology ETF ETF was 0%. For the same ETF, the average monthly price growth was 12%, and the average quarterly price growth was 9%. CRNX experienced the highest price growth at 116%, while DNA experienced the biggest fall at -12%.

Volume

The average weekly volume growth across all stocks in the iShares Biotechnology ETF ETF was 9%. For the same stocks of the ETF, the average monthly volume growth was -23% and the average quarterly volume growth was -28%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 59
P/E Growth Rating: 72
Price Growth Rating: 42
SMR Rating: 88
Profit Risk Rating: 83
Seasonality Score: 7 (-100 ... +100)
View a ticker or compare two or three
IBB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Category Health

Profile
Details
Category
Health
Address
iShares Trust400 Howard StreetSan Francisco
Phone
1-800-474-2737
Web
www.ishares.com
Interact to see
Advertisement
Aon plc (AON) reported third-quarter 2025 revenue of $3.997 billion, representing a 7% year-over-year increase with equal organic growth. Adjusted earnings per share came in at $3.05, exceeding expectations. In late November, Moody’s reaffirmed Aon’s Baa2 credit rating and revised the outlook to positive, citing reduced leverage following the NFP acquisition.
Air Products and Chemicals, Inc. (APD) entered the spotlight after announcing advanced discussions with Yara International on December 8 to collaborate on low-emission ammonia projects. While the strategic direction aligns with global decarbonization trends, uncertainty around execution and capital requirements triggered a 9.45% one-day decline in the stock.
Lockheed Martin and RTX Corporation are two of the most prominent names in the aerospace and defense industry, both positioned to benefit from heightened global security concerns and sustained U.S. military spending.
As 2025 winds down, the Savings Banks sector reflects a mix of stability, innovation, and AI-driven disruption. Among the most closely watched tickers—SOFI Technologies (SOFI), Ally Financial (ALLY), and PayPal Holdings (PYPL)—investors have witnessed contrasting stories of growth, valuation, and market perception.
Ondas Holdings (ONDS) is a wireless technology company focused on delivering secure, long-range communications for industrial Internet of Things (IoT) and data networking applications. Its solutions are built to support mission-critical operations across sectors such as rail, energy, maritime, infrastructure, and industrial automation.
Ciena’s growth is driven by expanding offerings in optical networking, network automation software, and 5G transport infrastructure, complemented by services designed to help customers modernize and future-proof their networks. Its evolving technology portfolio addresses the rising complexity, speed, and reliability requirements of today’s communications environment.
Marathon Digital Holdings (MARA) and Riot Platforms (RIOT) are two leading companies in the Bitcoin mining industry, each operating energy-intensive infrastructure to capitalize on cryptocurrency market cycles. This comparison is especially relevant amid ongoing Bitcoin price volatility and growing interest in digital assets and AI-related infrastructure.
Roivant Sciences has delivered strong year-to-date performance, with shares up roughly 82%, driven by encouraging pipeline developments and increased investment in high-potential subsidiaries such as Immunovant.
MP Materials Corp. (MP) and USA Rare Earth, Inc. (USAR) are central to the United States’ push to establish a secure, domestic supply of rare earth elements—materials critical to electric vehicles, renewable energy, and defense technologies. As geopolitical tensions and supply chain vulnerabilities intensify, these two companies offer distinct approaches to addressing U.S. dependence on foreign sources.
The Invesco QQQ Trust (NASDAQ: QQQ) remains one of the most closely followed ETFs worldwide, offering investors direct exposure to the NASDAQ-100 Index®. In the most recent data, QQQ has gained a notable +20.16% year-to-date, even as markets experienced bouts of elevated volatility.
Sidus Space has expanded its portfolio in 2025, focusing on satellite missions and supporting technologies to enhance space infrastructure. Key product advancements include the LizzieSat platforms, with multiple units progressing in design and manufacturing. LizzieSat-3 is set for launch no earlier than Q1 2025, building on prior missions to boost data capabilities for clients in Earth observation and communication.
As 2025 comes to a close, Dingdong (Cayman) Limited (DDL) continues to strengthen its position in China’s competitive fresh grocery e-commerce market. Operating from Shanghai, the company focuses on high-quality fresh produce, ready-to-eat meals, and daily essentials delivered directly to consumers. Throughout the year, Dingdong emphasized private-label expansion, supply-chain optimization, and fulfillment network growth—initiatives that supported improving quarterly performance and positioned the company for sustained momentum.
Pioneer Power's 2025 highlights include the expansion of its mobile power and charging footprint with new orders and partnerships; the launch of a new suite of e-Boost solutions for off-grid EV charging; the rebranding of HomeBoost as PowerCore with events in December; the introduction of PRYMUS in December; and a new five-year contract for network transformers with a regional utility provider.
An AI-driven comparison between Palantir (PLTR) and Oracle (ORCL) points to Palantir as the more compelling investment heading into 2026. The analysis highlights PLTR’s AI-native platforms, which enable real-time, data-driven decision-making across fast-growing sectors such as government, defense, and enterprise analytics.
An AI-driven comparison between D-Wave Quantum (QBTS) and IonQ (IONQ) points to IonQ as the stronger opportunity heading into 2026. The analysis highlights IONQ’s gate-based, trapped-ion quantum architecture, which supports a wide range of algorithms and positions the company for broader adoption across AI, simulation, and cryptography.
An AI-driven comparison of Rigetti Computing (RGTI) and D-Wave Quantum (QBTS) points to Rigetti as the more compelling opportunity heading into 2026. The analysis highlights RGTI’s gate-based quantum architecture, which supports universal quantum computing and a wide range of complex algorithms. While D-Wave remains a leader in quantum annealing for optimization problems, Rigetti’s full-stack, gate-based approach offers greater scalability and broader long-term applications.
An AI-driven comparison of Rigetti Computing (RGTI) and TeraWulf (WULF) points to TeraWulf as the more attractive investment heading into 2026. The analysis emphasizes WULF’s large-scale digital infrastructure supporting Bitcoin mining and high-performance computing (HPC), which generates immediate revenue in expanding digital asset and AI-driven markets.
An AI-driven comparison between Rocket Lab USA (RKLB) and Planet Labs (PL) identifies Rocket Lab as the more compelling investment heading into 2026. The analysis highlights RKLB’s vertically integrated space services and consistent launch performance, which position the company to benefit from rising demand for satellite deployment and space infrastructure.
An AI-driven comparison of Tempus AI (TEM) and Doximity (DOCS) points to Tempus AI as the more compelling investment opportunity heading into 2026. The analysis highlights TEM’s AI-powered precision medicine platform, which applies advanced analytics and genomic data to transform diagnostics and treatment in oncology and cardiology.
Three different biotech ETFs, three bearish signals with high confidence